JM-010: candidate for Levodopa-induced dyskinesia in Parkinson’s disease patients

  • Parkinson’s disease patients generally need to take L-dopa for a long time to ameliorate symptoms of the disease. About 90% of patients who have been taking L-dopa for 10 years or longer develop L-dopa-induced dyskinesia (LID), a kind of movement disorder, but there is no approved drug to treat this condition.

 

  • Bukwang strategically acquired 100% shares of Contera Pharma, a CNS-focused Danish bioventure company based in Copenhagen, to develop JM-010, an innovative treatment of dyskinesia in Parkinson's disease patients. Following completion of clinical Proof of Concept Study and Phase I PK Study in South Africa and Germany, respectively, a Phase II study in both US/EU is currently under preparation.

 

  • JM-010 is a combination of compounds, the safety of which has been already validated, which exerts efficacy against LID by controlling neurotransmitter release from the presynaptic neurons.

JM-010 : 파킨슨병 환자의 레보도파 유도 운동장애 치료제
|    ​Korean    |